期刊
LANCET
卷 377, 期 9769, 页码 942-955出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)61156-7
关键词
-
资金
- Sanofi-Aventis
- Serono Pharmaceuticals
- Merck Sorono
- National Health and Medical Research Council of Australia [510233, 568743]
- Motor Neurone Disease Research Institute
- Irish Health Research Board
- American ALS Association
- Irish Motor Neurone Disease Research Foundation
- Medical Research Council
- Clive and Vera Ramacciotti grant
- Charles Viertel grant
- Merck Serono Australia
- Novartis Australia
- Medical Research Council [G0701923] Funding Source: researchfish
- MRC [G0701923] Funding Source: UKRI
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. In this Seminar, we summarise current concepts about the origin of the disease, what predisposes patients to develop the disorder, and discuss why all cases of ALS are not the same. In the 150 years since Charcot originally described ALS, painfully slow progress has been made towards answering these questions. We focus on what is known about ALS and where research is heading-from the small steps of extending longevity, improving therapies, undertaking clinical trials, and compiling population registries to the overarching goals of establishing the measures that guard against onset and finding the triggers for this neurodegenerative disorder.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据